Source: Frontiers in Cardiovascular Medicine. Unidades: FM, FCF, ICB
Subjects: NANOPARTÍCULAS, ARTERIOSCLEROSE, DOENÇAS CARDIOVASCULARES, INFLAMAÇÃO, INTERLEUCINA 6
ABNT
MARINHO, Lucas Lage et al. Safety and possible anti-inflammatory effect of paclitaxel associated with LDL-like nanoparticles (LDE) in patients with chronic coronary artery disease: a double-blind, placebo-controlled pilot study. Frontiers in Cardiovascular Medicine, v. 11, p. 1-9, 2024Tradução . . Disponível em: https://dx.doi.org/10.3389/fcvm.2024.1342832. Acesso em: 20 ago. 2024.APA
Marinho, L. L., Rached, F. H., Morikawa, A. T., Tavoni, T. M., Cardoso, A. P. T., Torres, R. V. A., et al. (2024). Safety and possible anti-inflammatory effect of paclitaxel associated with LDL-like nanoparticles (LDE) in patients with chronic coronary artery disease: a double-blind, placebo-controlled pilot study. Frontiers in Cardiovascular Medicine, 11, 1-9. doi:10.3389/fcvm.2024.1342832NLM
Marinho LL, Rached FH, Morikawa AT, Tavoni TM, Cardoso APT, Torres RVA, Assunção Junior AN, Serrano Junior CV, Nomura CH, Maranhão RC. Safety and possible anti-inflammatory effect of paclitaxel associated with LDL-like nanoparticles (LDE) in patients with chronic coronary artery disease: a double-blind, placebo-controlled pilot study [Internet]. Frontiers in Cardiovascular Medicine. 2024 ; 11 1-9.[citado 2024 ago. 20 ] Available from: https://dx.doi.org/10.3389/fcvm.2024.1342832Vancouver
Marinho LL, Rached FH, Morikawa AT, Tavoni TM, Cardoso APT, Torres RVA, Assunção Junior AN, Serrano Junior CV, Nomura CH, Maranhão RC. Safety and possible anti-inflammatory effect of paclitaxel associated with LDL-like nanoparticles (LDE) in patients with chronic coronary artery disease: a double-blind, placebo-controlled pilot study [Internet]. Frontiers in Cardiovascular Medicine. 2024 ; 11 1-9.[citado 2024 ago. 20 ] Available from: https://dx.doi.org/10.3389/fcvm.2024.1342832